Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Ofrat Beyar Katz"'
Autor:
Ohad Benjamini, Shalev Fried, Roni Shouval, Jessica R. Flynn, Ofrat Beyar-Katz, Lori A Leslie, Tsilla Zucherman, Ronit Yerushalmi, Noga Shem-Tov, Maria Lia Palomba, Ivetta Danylesko, Inbal Sdayoor, Hila Malka, Orit Itzhaki, Hyung Suh, Sean M. Devlin, Ronit Marcus, Parastoo B Dahi, Elad Jacoby, Gunjan L Shah, Craig S Sauter, Andrew Ip, Miguel-Angel Perales, Arnon Nagler, Avichai Shimoni, Michael Scordo, Abraham Avigdor
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and effica
Externí odkaz:
https://doaj.org/article/446c107a98b1415f962e7e3be018edfa
Autor:
Ofrat Beyar-Katz, Jacob M. Rowe
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/ac39671ec1d844c3b922f2ba99de0f36
Autor:
Ofrat Beyar-Katz, Chava Perry, Yael Bar On, Odelia Amit, Odit Gutwein, Ofir Wolach, Rotem Kedar, Oleg Pikovsky, Irit Avivi, Ronit Gold, Jonathan Ben-Ezra, David Shasha, Ronen Ben Ami, Ron Ram
Publikováno v:
Annals of Hematology. 101:1769-1776
Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor response; however, impaired hematopoietic recovery is observed in about 30% of patients with prolonged cytopenia appearing as an unmet need for optimal treatm
Autor:
Ofrat Beyar Katz, Chava Perry, Sigal Grisariu‐Greenzaid, Dana Yehudai‐Ofir, Efrat Luttwak, Batia Avni, Tsila Zuckerman, Inbal Sdayoor, Polina Stepensky, Shimrit Ringelstein‐Harlev, Yael Bar‐On, Diana Libster, Liat Sharvit, Odelia Amit, Uri Greenbaum, Ronit Gold, Yair Herishanu, Noam Benyamini, Irit Avivi, Ron Ram
Publikováno v:
European Journal of Haematology.
Autor:
Yuval Shaked, Ron N. Apte, Elena Voronov, Marina Bersudsky, Noa Lavi, Michal Hayun, Shimrit Avraham, Michael Timaner, Yael Cohen, Irit Avivi, Noga Barak, Anat Reiner-Benaim, Ksenia Magidey, Ofrat Beyar-Katz
Multiple myeloma (MM) is a plasma cell neoplasia commonly treated with proteasome inhibitors such as bortezomib. Although bortezomib has demonstrated enhanced survival benefit, some patients relapse and subsequently develop resistance to such therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18c6c7c64a0ed62df3c722c385ba35f2
https://doi.org/10.1158/1541-7786.c.6541101
https://doi.org/10.1158/1541-7786.c.6541101
Autor:
Yuval Shaked, Ron N. Apte, Elena Voronov, Marina Bersudsky, Noa Lavi, Michal Hayun, Shimrit Avraham, Michael Timaner, Yael Cohen, Irit Avivi, Noga Barak, Anat Reiner-Benaim, Ksenia Magidey, Ofrat Beyar-Katz
Figure S1. Bone marrow-derived macrophages enrich MM TICs. Figure S2. IL-1β promotes MM-TIC enrichment. Figure S3. Reduced survival in MM patients with high levels of M1 pro-inflammatory macrophages and TICs. Table S1: Patient characteristics and tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46aa6d8376fed290c5d6a754f5bf3903
https://doi.org/10.1158/1541-7786.22515483
https://doi.org/10.1158/1541-7786.22515483
Autor:
Robert S. Kerbel, David Andrews, Valeria Miller, Florence T.H. Wu, Shan Man, Ping Xu, Ofrat Beyar-Katz, Ksenia Magidey, Santosh Hariharan, Elizabeth Pham, Yuval Shaked
Levels of viable CEPs in the blood of Balb/c mice treated with escalating doses of capecitabine (S1); A flow chart of the image analysis (S2); Colonization of bone marrow derived cells in tumors from mice treated with LDM or MTD capecitabine regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfda9d11d2091162a882ef8579babd8
https://doi.org/10.1158/0008-5472.22411463
https://doi.org/10.1158/0008-5472.22411463
Autor:
Yuval Shaked, Marcelle Machluf, Tomer Bronshtein, Ziv Raviv, Chen Rachman-Tzemah, Ofrat Beyar-Katz, Madeleine Benguigui, Ruslana Kotsofruk, Nitzan Letko-Khait, Michael Timaner
Supplemental Figures S1-7 supporting figures 1-6. Figure S1: Tumor growth in mice co�implanted with gemcitabine�educated MSCs and PANC1 cells. Figure S2: Viability and survival of TICs and MSCs in response to chemotherapy. Figure S3: TI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e12cf52774fb364cf33eef0014f1f4
https://doi.org/10.1158/0008-5472.22411733.v1
https://doi.org/10.1158/0008-5472.22411733.v1
Autor:
Robert S. Kerbel, David Andrews, Valeria Miller, Florence T.H. Wu, Shan Man, Ping Xu, Ofrat Beyar-Katz, Ksenia Magidey, Santosh Hariharan, Elizabeth Pham, Yuval Shaked
Panel of antibodies used for the mass cytometry assay (S1); Surface markers associated with metastasis (S2); Features extracted for each colony (S3).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b050adbb9fb1b5859cb0edaf35b42c
https://doi.org/10.1158/0008-5472.22411457.v1
https://doi.org/10.1158/0008-5472.22411457.v1
Autor:
Robert S. Kerbel, David Andrews, Valeria Miller, Florence T.H. Wu, Shan Man, Ping Xu, Ofrat Beyar-Katz, Ksenia Magidey, Santosh Hariharan, Elizabeth Pham, Yuval Shaked
Conventional chemotherapy drugs administered at a maximum tolerated dose (MTD) remains the backbone for treating most cancers. Low-dose metronomic (LDM) chemotherapy, which utilizes lower, less toxic, doses given on a close regular basis over prolong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::607a2d783b608acc25f1480a39ef2f9a
https://doi.org/10.1158/0008-5472.c.6508229.v1
https://doi.org/10.1158/0008-5472.c.6508229.v1